Edoxaban (Savaysa, Lixiana)

Anticoagulantprescriptionoral · inferred

Direct oral anticoagulant (DOAC) and selective, reversible factor Xa inhibitor. Rapid absorption (tmax 1-2h), moderate oral bioavailability (62%), primarily hepatic metabolism (CYP3A4) with minor renal elimination (35%). Terminal half-life 5-11h (shorter than other DOACs). No major active metabolites. Fixed dosing without monitoring. Approved for stroke prevention in nonvalvular atrial fibrillation and VTE treatment. Generally well-tolerated. Food increases bioavailability; administer with meals for optimal absorption. May have lower bleeding rates with respect to apixaban in some populations.

Projected serum levels — 60 mg, once daily

Maintenance schedule: 60 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 38.6 mg, trough ≈ 6.1 mg body load. Population-based estimate over 15 days for a 60 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category: Anticoagulant
Route modeled: Oral
Model confidence: inferred
Half-life: 12 h
Common dose: 60 mg
Suggested maximum: 60 mg/day
Reference dose range: 30–60 mg (single dose)
Suggested cadence: once daily
Validated against: 60 mg oral — Cmax 0.18 mg/L at 1.5 h

Documented interactions

danger
Carbamazepine (Tegretol) + Edoxaban (Savaysa, Lixiana) CYP induction
Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Edoxaban (Savaysa, Lixiana) AUC by ~0.33x
danger
Efavirenz (Sustiva) + Edoxaban (Savaysa, Lixiana) CYP induction
Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Edoxaban (Savaysa, Lixiana) AUC by ~0.22x
danger
Phenobarbital + Edoxaban (Savaysa, Lixiana) CYP induction
Phenobarbital inducer of CYP3A4 predicted to change Edoxaban (Savaysa, Lixiana) AUC by ~0.50x
danger
Phenytoin (Dilantin) + Edoxaban (Savaysa, Lixiana) CYP induction
Phenytoin (Dilantin) inducer of CYP3A4 predicted to change Edoxaban (Savaysa, Lixiana) AUC by ~0.50x
danger
Rifampin + Edoxaban (Savaysa, Lixiana) CYP induction
Rifampin inducer of CYP3A4 predicted to change Edoxaban (Savaysa, Lixiana) AUC by ~0.22x
danger
St. John's Wort (Hypericum perforatum) + Edoxaban (Savaysa, Lixiana) CYP induction
St. John's Wort (Hypericum perforatum) inducer of CYP3A4 predicted to change Edoxaban (Savaysa, Lixiana) AUC by ~0.40x

Serum checks 78 modeled interaction pairings for edoxaban (savaysa, lixiana) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans Parasrampuria DA et al. · Drug Metabolism and Disposition, 2012 DOI
Mass balance study showing edoxaban absorption, CYP3A4-mediated hepatic metabolism, renal and fecal elimination (97% recovery), and identification of inactive metabolites.
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa Ogata K et al. · Journal of Clinical Pharmacology, 2015 DOI
Comprehensive PK/PD review documenting edoxaban tmax 1-2h, bioavailability 62%, terminal half-life 5-11h, dose-proportional FXa inhibition, and clinical efficacy/safety.
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers Furugohri T et al. · Drug Metabolism and Disposition, 2010 DOI
Phase I study in healthy volunteers showing edoxaban single-dose PK, FXa inhibition kinetics, dose proportionality up to 150 mg, and excellent tolerability profile.

3 published studies referenced in the app, each with a plain-language summary.